SARS-CoV-2 nucleic acid testing is China's key pillar of COVID-19 containment
Xiaoxu Han,Jinming Li,Yu Chen,Yan Li,Yingchun Xu,Binwu Ying,Hong Shang
DOI: https://doi.org/10.1016/S0140-6736(22)00577-3
IF: 202.731
2022-01-01
The Lancet
Abstract:WHO states that timely and accurate diagnostic testing is an essential tool in preventing and controlling the spread of COVID-19.1WHORecommendations for national SARS-CoV-2 testing strategies and diagnostic capacities.https://www.who.int/publications/i/item/WHO-2019-nCoV-lab-testing-2021.1-engDate: Jun 25, 2021Date accessed: February 22, 2022Google Scholar With a huge and densely distributed population, China developed a national SARS-CoV-2 nucleic acid testing strategy that has had a pivotal role in containing COVID-19. This strategy involved border entry screening, inpatient screening, rapid screening in fever clinics, and mass screening of the population in an epidemic area.2Li ZJ Liu FF Cui JZ et al.Comprehensive large-scale nucleic acid-testing strategies support China's sustained containment of COVID-19.Nat Med. 2021; 27: 740-742Crossref PubMed Scopus (62) Google Scholar China began developing SARS-CoV-2 nucleic acid detection kits soon after the initial outbreak of COVID-19 in Wuhan at the end of 2019. By Jan 31, 2020, the National Medical Products Administration urgently approved six nucleic acid detection kits, and post-market evaluation with a multicentre clinical trial was completed by professional institutions by the end of February, 2020. The sensitivity of these kits was 55·3–95·7%, the specificity above 98% (unpublished). A national nucleic acid amplification testing (NAAT) laboratory network was also quickly established. NAAT laboratories have been in development across China for decades; thousands of NAAT laboratories for detecting infectious agents such as hepatitis B virus, hepatitis C virus, and HIV are established in large hospitals, blood centres, and in the Chinese Center for Disease Control and Prevention. As of Feb 14, 2022, 12 777 NAAT laboratories (four times more than at the beginning of the COVID-19 pandemic) provide strong support for infectious diseases diagnosis, treatment, and prevention (appendix). For every 1 million permanent urban residents, hospitals are equipped with at least one routine testing laboratory with capacity to analyse 10 000 samples per day. Professional education and technical training opportunities are also continuously provided to the laboratory staff by the National Center for Clinical Laboratories. Nationwide external quality assessment programmes are organised regularly for all testing laboratories (appendix). To detect COVID-19 outbreaks early and protect patients from getting infected in hospitals, all secondary and tertiary hospitals across China have fever clinics that provide services 24 h per day, 7 days a week. Fever clinics have been encouraged to acquire rapid SARS-CoV-2 testing tools that deliver results within 4–6 h and enable the timely identification of infections.3The Joint Prevention and Control Mechanism of the State CouncilNotice on further accelerating the improvement of novel coronavirus nucleic acid testing capacity in medical institutions.http://www.gov.cn/xinwen/2020–07/02/content_5523705.htmDate: Jun 30, 2020Date accessed: February 28, 2022Google Scholar China continues its population-based mass screening strategy to support the dynamic zero-COVID-19 policy. To implement such large-magnitude screening within epidemic areas in a short timeframe, routine testing laboratories in hospitals and public testing laboratories (including mobile laboratories and technical staff from surrounding neighbourhoods) can be mobilised urgently by the government. By the end of 2020, 100 mobile laboratories with a capacity to analyse 10 000 samples had been built, enabling a flexible testing reserve capacity of 1 million samples per day nationwide. Other large-scale and qualified independent clinical laboratories also participate in this mass screening strategy to accelerate sample testing turnover in every local epidemic area. To improve the efficiency of mass screening, China has adopted the sample pooling strategy in three patterns (five, ten, or 20 pooled samples) on the basis of different epidemic periods.4The Joint Prevention and Control Mechanism of the State CouncilTechnical specifications for the detection of SARS-CoV-2 nucleic acid with 10-in-1 pooled samples.http://www.gov.cn/xinwen/2020–08/19/content_5535756.htmDate: Aug 17, 2021Date accessed: February 23, 2022Google Scholar, 5The Joint Prevention and Control Mechanism of the State CouncilTechnical specifications for the detection of SARS-CoV-2 nucleic acid with 20-in-1 pooled samples.http://www.gov.cn/xinwen/2022–01/19/content_5669285.htmDate: Jan 15, 2022Date accessed: February 23, 2022Google Scholar With the optimisation of sample pooling methodology and development of an electronic information system, this sample pooling strategy ensures both high sensitivity and efficiency. The cost of routine SARS-COV-2 testing during hospitalisation and in fever clinics, as well as the mass screening during an epidemic, are covered by basic medical insurance or by the government. These measures enable large cities with a population of 10 million people or more to complete SARS-CoV-2 testing within 24–48 h, without substantially affecting routine clinical services.6Zhu WL Zhang MX Pan JH Yao Y Wang WB Effects of prolonged incubation period and centralized quarantine on the COVID-19 outbreak in Shijiazhuang, China: a modeling study.BMC Med. 2021; 19: 308Crossref PubMed Scopus (8) Google Scholar The SARS-CoV-2 testing strategy has not only improved the containment of COVID-19 but also contributes to the control of other infectious diseases, such as HIV and human papillomavirus, and non-communicable diseases. China's COVID-19 response has accelerated its diagnostics agenda and testing capacity. To further optimise the COVID-19 detection strategy, China recently decided to supplement the existing strategy with antigen detection, and we will continue to accelerate technological innovation and develop the testing reagents for communities and remote areas. Ensuring universal access to diagnostics via effective and rapid testing is essential for the preparations for future pandemics. This online publication has been corrected. The corrected version first appeared at thelancet.com on April 13, 2022 This online publication has been corrected. The corrected version first appeared at thelancet.com on April 13, 2022 HS is director of the National Clinical Research Center for Laboratory Medicine, which provides technical support for the national strategy of COVID-19 testing. All other authors declare no competing interests. Download .pdf (.66 MB) Help with pdf files Supplementary appendix Department of ErrorHan X, Li J, Chen Y, Li Y, Xu Y, Ying B, Shang H. SARS-CoV-2 nucleic acid testing is China's key pillar of COVID-19 containment. Lancet 2022; published online April 7. https://doi.org/10.1016/S0140-6736(22)00577-3—In this Correspondence, the authors' competing interests statement should have declared that HS is director of the National Clinical Research Center for Laboratory Medicine, which provides technical support for the national strategy of COVID-19 testing, and that all other authors declare no competing interests. Full-Text PDF